Subscribe: Market Wire - Pharmaceuticals and Biotech: Trials
http://img.marketwire.com/rss/mwPBTR.rss
Preview: Market Wire - Pharmaceuticals and Biotech: Trials

Marketwired - Trials



Marketwired - Trials



Last Build Date: Fri, 16 Feb 2018 18:07:33 EST

Copyright: Copyright: (C) Marketwired
 



Pieris Pharmaceuticals Announces Closing of Public Offering and Exercise of Underwriters' Option to Purchase Additional Shares

Fri, 16 Feb 2018 17:36:17 EST

BOSTON, MA--(Marketwired - February 16, 2018) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, announced today the closing of its previously announced underwritten public offering and the exercise in full of the underwriters' option to purchase additional shares. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Pieris, are $50.6 million. 6,325,000 shares of common stock at a public offering price of $8.00 per share were issued and sold in the offering, which includes 825,000 shares issued upon the exercise of the underwriters' option to purchase additional shares, less the underwriting discounts and commissions.




Moleculin Announces Pricing of $9 Million Registered Direct Offering

Fri, 16 Feb 2018 08:28:56 EST

HOUSTON, TX--(Marketwired - February 16, 2018) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that it has entered into a definitive agreement with institutional investors for a registered direct offering of securities with gross proceeds of approximately $9 million. The closing of the offering is expected to take place on or about February 21, 2018, subject to the satisfaction of customary closing conditions.




Moleculin Announces Breakthrough Discovery of a New Molecule for Cancer Treatment

Thu, 15 Feb 2018 08:30:00 EST

Cutting Edge Science Suggests New Molecule Is Capable of Shutting Down Tumor Activity




Pieris Pharmaceuticals Announces Pricing of its Public Offering

Wed, 14 Feb 2018 00:27:18 EST

BOSTON, MA--(Marketwired - February 14, 2018) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, announced today the pricing of its previously announced underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $8.00 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Pieris, are expected to be $44.0 million. In addition, Pieris has granted the underwriters a 30-day option to purchase up to 825,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about February 16, 2018, subject to customary closing conditions.




Acasti Pharma Reports Third Quarter FY 2018 Financial Results

Tue, 13 Feb 2018 17:00:00 EST

Increased Cash Position Supports Initiation of CaPre Phase 3 Clinical Studies




Pieris Pharmaceuticals Announces Public Offering of Common Stock

Tue, 13 Feb 2018 16:01:00 EST

BOSTON, MA--(Marketwired - February 13, 2018) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. Pieris intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in the offering at the public offering price, less the underwriting discounts and commissions. All of the shares in the offering will be sold by Pieris.




Moleculin Announces Collaboration with Emory University to Develop Novel Treatment of Pediatric Brain Cancer

Tue, 13 Feb 2018 08:30:00 EST

HOUSTON, TX--(Marketwired - February 13, 2018) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has entered into an agreement with Emory University to enable expanded cancer research on Moleculin's WP1066 molecule for the possible treatment of medulloblastoma, a pediatric malignant primary brain tumor.




VistaGen Therapeutics Reports Third Quarter Fiscal 2018 Financial Results

Mon, 12 Feb 2018 16:30:00 EST

SOUTH SAN FRANCISCO, CA--(Marketwired - February 12, 2018) - VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, today reported financial results for its third fiscal quarter ended December 31, 2017.